Publications by authors named "Virginia Paton"

Claim this Profile
M
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
Melody A Cobleigh, Charles L Vogel, Debu Tripathy, Nicholas J Robert, Susy Scholl, Virginia Paton

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Virginia Paton

Clin Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, Chia-Chi Lin, Chia-Jui Yen, Virginia Paton

J Immunother Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Michael Friedlander, Tarek Meniawy, Ben Markman, Linda Mileshkin, Paul Harnett, Virginia Paton

Lancet Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
David R Spigel, Martin J Edelman, Kenneth O'Byrne, Luis Paz-Ares, Simonetta Mocci, Virginia E Paton

J Clin Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.
Roland Morley, Alison Cardenas, Peter Hawkins, Yasuyo Suzuki, Virginia Paton

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Darrell White, Adetola Kassim, Birbal Bhaskar, Jing Yi, Karen Wamstad, Virginia E Paton

Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
Stuart D Russell, Kimberly L Blackwell, Julia Lawrence, John E Pippen, Matthew T Roe, Virginia Paton

J Clin Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Sharmila Makhija, Lukas C Amler, Dana Glenn, Frederick R Ueland, Michael A Gold, Virginia Paton

J Clin Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Louis P Garrison, Deborah Lubeck, Deepa Lalla, Virginia Paton, Amylou Dueck

Cancer· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
Adam Brufsky, Barry Lembersky, Kathy Schiffman, Grazyna Lieberman, Virginia E Paton

Clin Breast Cancer· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Debu Tripathy, Andrew Seidman, Deborah Keefe, Clifford Hudis, Virginia Paton

Clin Breast Cancer· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation.
Paul J Martin, Joseph H Antin, Daniel J Weisdorf, Virginia Paton, Mary M Horowitz

Biol Blood Marrow Transplant· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac dysfunction in the trastuzumab clinical trials experience.
Andrew Seidman, Clifford Hudis, Mary Kathryn Pierri, Steven Shak, Virginia Paton

J Clin Oncol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis